10/564720 IAP6 Rec'd PCT/PTO 17 JAN 2006

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

3 2 p. . . st

Docket No: Q92718

Haruo IMAWAKA, et al.

Appln. No.: National Stage Entry of PCT/JP2004/010366

Confirmation No.: Unknown Group Art Unit: Unknown

Filed: January 17, 2006 Examiner: Unknown

For: BRANCHED CARBOXYLIC ACID COMPOUND AND USE THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith on CD-ROM, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

10/564720

IAPS Rec'd PCT/PTO 17 JAN 2006

INFORMATION DISCLOSURE STATEMENT National Stage Entry of PCT/JP2004/010366

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant encloses herewith a copy of a Communication from a

foreign patent office in a counterpart application citing such documents (International Search

Report for PCT/JP2003/010366 dated November 22, 2004), together with an English-language

version (if not already included) of at least that portion of the Communication indicating the

degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: January 17, 2006

Mark Boland

Registration No. 32,197

MAPS Rec'd PCT/PTO 17 JAN 2006

Attorney Docket Number

MODIFIED PTO/SB/08 A & B (06-03)

Q92718

10/564720 Complete if Known Substitute for Form 1449 A & B/PTO National Stage Entry of Application Number PCT/JP2004/010366 INFORMATION DISCLOSURE Unknown Confirmation Number STATEMENT BY APPLICANT January 17, 2006 Filing Date Haruo IMAWAKA First Named Inventor (use as many sheets as necessary) Unknown Art Unit Examiner Name Unknown

Sheet

			U.S.	PATENT DOCUM	ENTS
Examiner Initials*	Cite No.1	Document	Number		
		Number	Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US			
Ī		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		JР	60-4182	A	01-11-1985	Yamanouchi Pharmaceutical Co., Ltd.	
		JР	4-279576	Α	10-05-1992	Tanabe Seiyaku Co., Ltd.	
		JP	62-277375	Α	12-02-1987	BASF AG.	
		WO	03/07992	A1	01-30-2003	Ono Pharmaceutical Co., Ltd.	
		JP	7-316092	Α	12-05-1995	Ono Pharmaceutical Co., Ltd.	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.				
		International Search Report dated November 22, 2004				
		Anthony J. Manny, et al., "Reinvestigation of the sulfuric acid-catalyzed cyclization of brominated 2-alkyllevulinic acids to 3-alkyl-5-methylene-2 (5H)-furanones, Tetrahdron", 1997, 15813 to 15826				
		Howard T. Black, et al., "Synthesis of 3, 5-disubstituted butenolides. A short preparation of volatile streptomyces lactones, Synthetic Communications", 1995, 25 (4), 479-483				
		Norihiko Yoneda, et al., "Reaction behavior of carbon-carbon and carbon-hydrogen bonds in super acids. Carboxylation of alkyl methyl ketones with carbon monoxide and water", Chemistry Letters, 1983, (1), 19-20				
		Hermann Stetter, et al., "Addition of aldehydes to activated double bonds. XXV. Syntheses and reactions of branched tri-carbonyl compounds", Chemische Berichte, 1981, 114 (2), 564-580				
		Tomoyuki Hasegawa, et al., "A practical synthesis of optically active (R) -2-propyloctanoic acid: therapeutic agent for Alzheimer's disease", Bulletin of the Chemistry Society of Japan, 2000. 73 (2), 423-428				
		Tomoyuki Hasegawa, et al., "A practical synthesis of optically active (R) -2-propyloctanoic acid: therapeutic agent for Alzheimer's disease", Bulletin of the Chemistry Society of Japan, 2000. 73 (2), 423-				

Examiner Signatu	ro l	l Da	ite Considered	
Examinet Signatu	16	Da	ite Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.